Morphotek Inc. Announces Collaboration Agreement With University of Wisconsin-Madison To Study The Immunosuppressive Effects Of Ca125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer
EXTON, Pa., Dec. 3, 2015 /PRNewswire/ -- Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of Wisconsin-Madison (UW-Madison) to elucidate the immunosuppressive effects of the CA125 tumor antigen on the investigational monoclonal antibody farletuzumab.
Farletuzumab is a humanized monoclonal antibody (mAb) that binds to folate receptor alpha (FRA), a cell-surface protein highly expressed in ovarian carcinoma but largely absent from normal tissue. Previously published work by researchers at UW-Madison showed that the human CA125 tumor antigen may potentially suppress immune-mediated killing of macrophages and natural killer (NK) cells by suppressing their antibody-dependent cellular cytotoxicity (ADCC) function. ADCC is an immune-mediated cell-killing process inherent to macrophages and NK cells that is activated through the engagement of mAbs bound to cell-surface tumor antigens. Farletuzumab is an investigational mAb that targets tumor cells through binding the cell surface-expressed FRA and mediates tumor cell killing in part by ADCC. CA125 is a secreted protein highly over-expressed by the majority of ovarian cancers. Previous independent studies suggest that one of CA125's pro-tumor functions is to enable tumors to avoid immune-mediated killing by the patient's own immune system.
The collaboration will initially investigate the immune status of primary macrophage and NK cells derived from the blood of ovarian cancer patients with varying levels of CA125. In addition, the collaboration will test whether the farletuzumab-mediated killing of ovarian cancer cells using patient-derived immune cells is affected by tumor-derived CA125.
"We are excited to enter this collaboration with researchers at the University of Wisconsin-Madison in this innovative field of CA125-mediated immune suppression," stated Luigi Grasso, Ph.D., Chief Scientific Officer of Morphotek. "Our efforts to understand the mechanisms by which tumors evolve to evade immune surveillance, including ADCC suppression, will continue to enable us to develop novel therapeutic agents and innovative clinical designs to overcome these mechanisms and potentially aid patients with malignancies over-expressing CA125."
As ADCC is an important mechanism of action of farletuzumab, higher levels of CA125 may potentially disrupt the ability of farletuzumab to elicit an ADCC response, thereby lowering its anti-FRA-mediated tumor-killing potential. To potentially minimize the effect of CA125-based suppression of ADCC in patients, Morphotek recently initiated a clinical research study in platinum-sensitive ovarian cancer patients with low CA125 levels. The double-blind, randomized, controlled study is designed to prospectively evaluate the clinical effects observed in the previously conducted Phase 3 trial in the pre-specified subset of patients treated with farletuzumab exhibiting low CA125 levels. Further information on the new clinical study can be found at www.clinicaltrials.gov, study number NCT02289950.
Morphotek®, Inc., a subsidiary of Eisai Inc., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of a novel and proprietary gene evolution technology. The technology has been successfully applied to a broad variety of cell lines and organisms to yield genetically diverse offspring that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com.
Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/morphotek-announces-collaboration-agreement-with-university-of-wisconsin-madison-to-study-the-immunosuppressive-effects-of-ca125-tumor-antigen-on-immune-based-therapies-for-ovarian-cancer-300187263.html
SOURCE Morphotek, Inc.